Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HIND
stocks logo

HIND

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast HIND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIND is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HIND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIND is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.980
sliders
Low
15.00
Averages
15.00
High
15.00
Current: 4.980
sliders
Low
15.00
Averages
15.00
High
15.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Vyome Holdings Inc (HIND.O) is -5.41, compared to its 5-year average forward P/E of -9.01. For a more detailed relative valuation and DCF analysis to assess Vyome Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.01
Current PE
-5.41
Overvalued PE
-3.31
Undervalued PE
-14.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HIND News & Events

Events Timeline

(ET)
2025-09-29
07:34:29
Vyome Holdings Purchases Oculo Health, an AI Spinout from MIT
select
2025-09-17 (ET)
2025-09-17
07:13:19
Vyome Holdings Reveals Findings from Preclinical Studies of VT-1908
select
2025-09-09 (ET)
2025-09-09
09:05:53
Vyome Holdings names Richard Fahrner as Chief Technology Officer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-21Newsfilter
Harvest ETFs Reveals Distribution Plans for November 2025

  • Monthly Distributions Announcement: Harvest Portfolios Group Inc. has announced monthly distributions for various Harvest ETFs for November 2025, with payments scheduled for December 5, 2025, to unitholders of record on November 28, 2025.

  • Distribution Details: The distributions vary by ETF, with amounts ranging from $0.0250 to $0.4300 per unit, depending on the specific ETF and its currency denomination.

  • Estimated Distribution for Canadian T-Bill ETF: An estimated distribution of $0.0935 per unit for the Harvest Canadian T-Bill ETF will also be paid on December 5, 2025, with the final amount to be confirmed on November 27, 2025.

  • Company Background: Harvest Portfolios Group Inc., founded in 2009, manages over $9.6 billion in assets and focuses on long-term wealth preservation through high-quality business investments, utilizing various covered call strategies across its ETFs.

[object Object]
Preview
8.5
11-18Newsfilter
Vyome Holdings Reports Significant First Quarter After Nasdaq Listing

  • Corporate Milestones: Vyome Holdings successfully completed a streamlined Nasdaq listing and reported encouraging interim Phase 2 results for its drug VT-1953, aimed at treating malignant fungating wounds, while maintaining a disciplined cash burn rate that extends its runway through 2026.

  • Leadership and Strategy: The company appointed a new CTO and SVP of Clinical Development with extensive Big Pharma experience and launched an AI strategy through the acquisition of MIT startup Oculo, enhancing its capabilities in drug development.

  • Clinical Progress: VT-1953 demonstrated significant reductions in malodor and pain in patients, with plans for FDA discussions on pivotal study design and orphan drug designation in 2026, targeting a $1 billion market opportunity with no existing FDA-approved treatments.

  • Financial Overview: As of September 30, 2025, Vyome reported total cash of $5.7 million, a clean capital structure with no preferred stock, and a net loss primarily due to one-time merger-related expenses, reflecting a strong position for future growth.

[object Object]
Preview
8.5
09-29Newsfilter
Vyome Holdings Purchases Oculo Health, an AI Spinout from MIT

  • New AI Business Unit: Vyome Holdings has launched a new business unit focused on developing an AI psychiatrist aimed at reducing inflammation, leveraging assets acquired from the AI startup Oculo, Inc.

  • Funding and Market Potential: Vyome is fully funded through 2026 and aims to create a new therapeutic category at the intersection of mental health and digital health, with a market potential exceeding $100 billion in digital therapeutics over the next decade.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vyome Holdings Inc (HIND) stock price today?

The current price of HIND is 4.98 USD — it has decreased -2.16 % in the last trading day.

arrow icon

What is Vyome Holdings Inc (HIND)'s business?

Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

arrow icon

What is the price predicton of HIND Stock?

Wall Street analysts forecast HIND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIND is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vyome Holdings Inc (HIND)'s revenue for the last quarter?

Vyome Holdings Inc revenue for the last quarter amounts to 34.63K USD, decreased -98.49 % YoY.

arrow icon

What is Vyome Holdings Inc (HIND)'s earnings per share (EPS) for the last quarter?

Vyome Holdings Inc. EPS for the last quarter amounts to -3.06 USD, decreased -99.02 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vyome Holdings Inc (HIND)'s fundamentals?

The market is revising No Change the revenue expectations for Vyome Holdings, Inc. (HIND) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -37.36%.
arrow icon

How many employees does Vyome Holdings Inc (HIND). have?

Vyome Holdings Inc (HIND) has 17 emplpoyees as of December 05 2025.

arrow icon

What is Vyome Holdings Inc (HIND) market cap?

Today HIND has the market capitalization of 28.73M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free